Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Michael Jaimes

Vascular & Interventional Radiology Austin, TX Medical Doctor

NPI 1073715884 CMS profile 185322

12554 Riata Vista Cir, Austin, TX 78727

Open in the dashboard

General payments

$92,997

186 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michael Jaimes of Austin, TX is reported in the CMS Open Payments database as having received $92,997 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $141 3
2023 General $10,127 17
2022 General $22,233 37
2021 General $640 11
2020 General $31,910 57
2019 General $27,948 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Jaimes
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Michael Jaimes were reported at $0. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Michael Jaimes Vascular & Interventional Radiology median Middle half National median
2019 $27,948 $422 $125–$1,555 $163
2020 $31,910 $200 $68–$652 $114
2021 $640 $280 $99–$866 $132
2022 $22,233 $433 $137–$1,497 $149
2023 $10,127 $506 $152–$2,019 $160
2024 $141 $556 $175–$1,930 $164
2025 $0 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Sirtex Medical Inc $91,143 146 payments
  2. Boston Scientific Corporation $798 25 payments
  3. Penumbra, Inc. $235 2 payments
  4. Medtronic USA, Inc. $203 1 payment
  5. Medtronic, Inc. $158 2 payments
  6. Medtronic Vascular, Inc. $145 2 payments
  7. Phathom Pharmaceuticals, Inc. $95 1 payment
  8. Cumberland Pharmaceuticals, Inc. $71 1 payment
  9. Cook Medical LLC $58 1 payment
  10. HealthTronics Mobile Solutions, LLC $28 1 payment
  11. Other $64 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $74,500 30 payments
  2. Travel and Lodging $8,339 60 payments
  3. Honoraria $6,000 3 payments
  4. Food and Beverage $4,158 93 payments
Products named General payments · program years 2019–2024
  1. SIR-Spheres Microspheres $91,143 146 payments
  2. TheraSphere Y90 Glass Microspheres 10 GBq $272 9 payments
  3. KYPHON Balloon Kyphoplasty $203 1 payment
  4. Ruby $125 1 payment
  5. HawkOne Directional Atherectomy Devices $119 1 payment
  6. RUBY Coil $110 1 payment
  7. VOQUEZNA $95 1 payment
  8. ICEfx Cryoablation System $87 1 payment
  9. Abre $84 1 payment
  10. HawkOne Directional Atherectomy Devices $73 1 payment
  11. Other $470 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$102,330

Of which drugs: $276

Medicare patients

1,780

Average age 76

Services billed

5,562

1,006 women, 774 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 44%
Diabetes 41%
Depression 39%
Heart failure 35%
Chronic kidney disease 35%
Atrial fibrillation 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 34 2,975 $273

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $95
$95 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record